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Introduction
　Early diagnosis and appropriate treatment strategies, such 
as endoscopic resection and surgical management, have 
made gastric cancer a curable disease.  However, approxi-
mately half of newly diagnosed patients bear more advanced-
stage disease [1] and often experience recurrence or metas-
tasis even after undergoing curative surgery. A sustained 
pursuit for the pathogenesis of gastric cancer has revealed 
that various factors, including diets high in salt, a low intake 
of fruits and vegetables and chronic inflammation induced 
by Helicobacter pylori infection, are associated with car-
cinogenesis [2] [3] [4].  In addition to these etiologic factors, 
multiple genetic and epigenetic alterations are implicated in 
the multistep process of the development and spread of gas-
tric cancer, including lymph node metastasis and peritoneal 
dissemination [5, 6].  However, even with the advent of mo-
lecular biology, the precise mechanisms involved in these 
processes remain to be elucidated.
　Recently, cancer stem cells, defined as cancer cells having 
the capacity for self-renewal, thereby giving rise to a hetero-
geneous lineage of cancer cells that eventually constitute a 
tumor, have been reported to be involved in the carcinogen-
esis of a variety of malignancies [7].  In this concept, called 
the cancer stem cell (CSC) theory, CSCs play a crucial role 
in metastasis.  Failure to eliminate CSCs may be attributed 
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to recurrence following curative treatment [8].  This theory 
was first described in relation to hematopoietic malignancy; 
however, the concept has achieved popularity with respect to 
the exploration of carcinogenesis in patients with solid tu-
mors, such as those of the breast [9], brain [10], colon [11, 
12], prostate [13], head and neck [14] and liver [15].  In this 
context, CSCs may also be involved in the establishment of 
secondary metastatic tumors in distant organs due to their 
tumor-initiating capacity [16].  Many putative cell surface 
markers (CSC markers) are reported to identify CSC popula-
tion so far.  In gastric cancer, some authors also have re-
vealed a correlation between these CSC markers such as 
CD44 and CD133 and poor prognoses using immunohis-
tochemistry[17-20].  
　To improve prognosis of gastric cancer, it is important to 
select the patients with worse prognosis for candidate of ad-
juvant treatment.  However, it is unknown which CSCs 
marker could be more effective to select the patients with 
worse prognosis.  In addition, immunohistochemical stain 
sometimes show false positive.  To pick these patients up 
thoroughly, we performed combined detection of two repre-
sentative CSC markers, CD44 and CD133, which may be 
expressed in cancer stem cells in various types of tumors. 
We considered patients with gastric cancer deeply penetrat-
ing the gastric wall (T3/4a) to be good candidates for an 
analysis to elucidate the significance of the expressions of 
CSC markers in tumor spread.  Hence, we selected patients 
with T3a/4 gastric cancer for this study.  Our results indicate 
that positivity for CSC markers is a useful biomarker for pre-
dicting the outcome of advanced gastric cancer.
Materials and Methods
Patients
　Among the 256 patients who underwent gastrectomy at 
Nagasaki University Hospital between 2002 and 2006, 73 
patients who were treated with curative surgery and had 
pathologically proven T3/4a gastric adenocarcinoma were 
enrolled in this study.
　The demographic data of all patients were recorded, and 
TNM staging was performed according to the Japanese Clas-
sification of Gastric Carcinoma issued by the Japanese Re-
search Society for Gastric Cancer [21]. The histological type 
was classified as differentiated or undifferentiated. Well- and 
moderately-differentiated tubular or papillary adenocarcino-
mas were classified as differentiated.  The undifferentiated 
group consisted of poorly-differentiated adenocarcinoma, 
signet-ring cell carcinoma and mucinous adenocarcinoma.
Immunohistochemistry
　Formalin-fixed and paraffin wax-embedded gastric cancer 
specimens obtained from 73 patients were investigated.  He-
matoxylin and eosin staining was used for the histological 
study, and one block with maximal section of tumoral tissue 
was chosen for immunostaining.  The specimens were cut 
into 4-microm-thick sections, which were dewaxed and 
stained using the streptavidin-biotin-peroxidase complex 
method. For antigen retrieval, the slides were heated at 95c 
for 20 minutes in a microwave oven for CD44 staining or 
125c for 10 minutes for CD133 staining.  The sections were 
incubated with antibodies at the following dilutions: primary 
anti-CD44 antibodies (Novacastra; Newcastle, UK) at 1:100 
and anti-CD133 antibodies (Cell Signaling Technology, 
Danvers, MA, USA) at 1:100.  The sections were incubated 
with secondary antibodies for 60 minutes at room tempera-
ture.  The slides were washed three times with Tris-Buffered 
saline (TBS), followed by incubation with Envision kit/HRP 
(Dako, Glostrup, Denmark) for 30 minutes (CD44) or CSAII 
(Dako, Glostrup, Denmark) for 15 minutes (CD133).  After 
being washed three times with TBS, each slide was incu-
bated for 5 minutes in 2% 3,3ʼ-diaminobenzidine tetrahydro-
chloride 50 mM tris-buffer (pH 7.6) containing 0.3% hydro-
gen peroxidase as a chromogen, then counterstained with 
hematoxylin. Tumors with more than 5% membranous 
stained cancer cells were regard as being positive for CD44 
[17].  Tumors with at least one cell with membranous or cy-
toplasmic staining per 10 high power fields were designated 
as being CD133-positive.  All sections were evaluated by a 
pathologist who was unaware of the clinical outcomes of the 
patients.
Statistical analysis
　The correlations between the expressions of CD44 and 
CD133 and the clinicopathologic factors were analyzed us-
ing Studentʼs t-test and the chi-square test.  A survival analy-
sis was performed using the Kaplan-Meier method, and sur-
vival differences were analyzed using the log-rank test.  A 
Cox regression model was used to evaluate the associations 
between the clinical covariates and cancer-specific survival. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) 
were estimated from the Cox proportional hazard models. 
For the multivariable analysis, all variables that were moder-
ately associated with cancer-specific survival were included 
(p<0.10).  Differences at p<0.05 were considered to be sig-
nificant.  All statistical analyses were performed using the 
Statview software program.
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The CD44 and CD133 expressions in gastric cancer
　The patients in this study included 52 males and 21 fe-
males 35 to 90 years of age (median: 70.0 years of age). All 
patients were followed up for survival, and 63 patients whose 
data were available were also followed up for recurrence-
free survival. Recurrence was defined as initial tumor recur-
rence, and only deaths from cancer were considered in the 
analysis of survival in this study.
　Forty-six percent of the patients were CD44-positive and 
54% were CD44-negative. The CD44 expression was intense 
primarily on the cell membranes of the cancer tissues, and 
none of the patients exhibited CD44 staining in the cyto-
plasm (Fig.1A).  In contrast, CD133 staining was observed 
in either the cytoplasm or apical membrane of the tumor 
cells.  Of the 73 gastric cancer specimens, 23 tumor tissues 
(31.5%) exhibited positive immunoreactivity for CD133 
(Fig.1B).  A majority of the CD44-positive cases demon-
strated large distribution of positive cells.  On the other hand, 
CD133-positive cells were rare.  In both CD44 and CD133 
staining, there were no differences in the distribution of pos-
itive cells between the tumor surface and more deeply inva-
sive areas.
CD44 and CD133 expressions associated with clinicopatho-
logical features
　The relationships between CSC marker staining and clini-
copathological characteristics were examined (Table 1). 
There were no significant correlations between the CD44 ex-
pression and clinicopathological factors such as tumor his-
tology and lymph node metastasis.  The CD133-positive 
gastric cancer patients exhibited larger tumor sizes and more 
lymphatic invasion than the CD133-negative patients with 
marginal statistical significance.
The CSC marker expression and survival
　To investigate the clinical impact of the expressions of 
CSC markers in patients with gastric cancer, we performed 
combined detection of CD44 and CD133.   We classified the 
73 patients into CSC marker-positive and -negative groups. 
The CSC marker-positive group included CD44- and/or 
CD133-positive patients, for a total of 40 patients.  The CSC 
marker-negative group included patients with both CD44- 
and CD133-negative staining, consisting of 33 patients. 
There were 12 patients with both CD44- and CD133-posi-
tive staining; however, the distribution of each CD44 and 
CD133 positive cells was quite different.
　There were no correlations between CSC marker positiv-
ity and the extent of lymph node metastasis, although we did 
find a significant correlation between the CSC marker ex-
pression and factors such as lymphatic and vessel invasion.
　Next, we investigated the correlations between the ex-
pressions of CSC markers and the prognoses of the patients. 
The median follow-up time was 928 days (range, 14 to 3,582 
days).  Among these patients, the date of recurrence was un-
certain in 10 patients who died from cancer.  Therefore, re-
currence-free survival was investigated in 63 patients.
　Table 2 lists the site of first tumor recurrence in the two 
groups.  The most frequent site of recurrence in both groups 
was the peritoneum, and the pattern of recurrence was simi-
lar between the two groups.
　Fig.2 shows the Kaplan-Meier curves for survival in the 
two groups of gastric cancer patients subdivided according 
to the expressions of the CSC markers.  The patients in the 
CSC marker-positive group exhibited poorer prognoses (log-
rank test, p=0.006) than those in the CSC marker-negative 
group.  The recurrence-free survival of the CSC marker-pos-
itive group was also significantly worse than that of the CSC 
marker-negative group (log-rank test, p=0.019) (Fig.3).
　In order to identify significant risk factors for cancer-spe-
cific survival in the 73 patients with T3/4a gastric cancer 
Results
Figure 1. Representative images of immunohistochemical staining 
for CD44 and CD133.  (A) CD44 was expressed prominently in 
the membranes of the cancer cells (x400).  (B) CD133 positivity 
was found in the cytoplasm of the cancer cells (x400).
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who underwent curative surgery, a multivariate analysis was 
performed (Table 3).  First, a univariate analysis of the six 
clinicopathological factors was carried out.  Based on the 
results of the univariate analysis, lymph node metastasis 
(p<0.001), lymphatic invasion (p=0.09) and CSC marker 
positivity (p<0.01) were included as covariates in the multi-
variate regression analysis.  The results revealed that second 
to lymph node metastasis, CSC marker positivity was a sta-
tistically significant risk factor for overall survival. The CSC 
marker expression was found to be a statistically significant 
prognostic factor in patients with T3/4a gastric cancer.
　Recently, cancer stem cell (CSC) theory was introduced 
into the field of cancer research.  Due to their tumor-initiat-
ing capacity, CSCs are involved in the establishment of sec-
ondary metastatic tumors in distant organs.  With regard to 
peritoneal dissemination, Nishii et al. reported that CSC 
markers, such as CD44 and Sox2, are significantly overex-
pressed in tumor cells constituting the bulk of peritoneal dis-
semination in animal models [22]. Their results imply the 
existence of a correlation between stemness and the devel-
opment of peritoneal dissemination; however, few clinical 
studies using immunohistochemistry to evaluate the signifi-
cance of the CSC marker expression have been reported thus 
far.
　In order to investigate the role of CSC markers in gastric 
cancer metastasis and the possibility to pick patients with 
worse prognosis up in clinical practice, we performed com-
bined detection of two representative CSC markers in pa-
tients with advanced gastric cancer, i.e., tumors invading the 
subserosa or penetrating the serosa (T3/4a).  To minimize 
bias from the operative procedures, we excluded patients 
with tumor invasion to adjacent organs because such tumors 
require combined resection of the involved organs.
　Various CSC markers have been reported thus far, includ-
Table 1. Association of  CSCs marker staining with clinicopathological features of gastric cancer 
Variables
CD44 expression CD133 expression CSC marker expression
Positive Negative P-value Positive Negative P-value Positive Negative P-value
(n=29) (n=44) (n=23) (n=50) (n=40) (n=33)
Age (yr) 69.3 +/- 1.88  67.4 +/- 1.65 0.43 70.1 +/- 1.59 67.2 +/- 1.65 0.28 70.0 +/- 1.46 66.0 +/- 2.06 0.11
Sex 0.65 <0.05 0.44
   Male 22 30 22 30 33 19
   Female 7 14 1 20 7 14
Tumor size (mm) 61.7 +/- 4.70 62.9 +/- 5.71 0.89 72.8 +/- 7.59 57.6 +/- 4.37 0.07 66.8 +/- 5.22 57.1 +/- 5.79 0.22
Histology >0.99 0.21 0.48
   Differentiated 12 18 12 18 18 12
   Undifferentiated 17 26 11 32 22 21
Lymphatic invasion 0.44 0.05 0.04
   ly0-1 7 15 3 19 8 14
   ly2-3 22 29 20 31 32 19
Vessel invasion 0.08 0.08 <0.01
   v0-1 7 20 5 22 8 14
   v2-3 22 24 18 28 32 19
Lymph node metastasis 0.62 0.80 >0.99
   N0-1 17 29 14 32 25 21
   N2-3 12 15 9 18 15 12




Site of first recurrence 0.33
  Peritoneal 12 6
  Lymph nodes 6 1
  Liver 3 0
  Others 3 3
Discussion
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ing CD44 and CD133.  CD44, a transmembrane glycopro-
tein, is involved in cellular adhesion and motility in response 
to the microenvironment [23].  Furthermore, CD44 is known 
to be a determinant of metastatic and invasive behavior in 
different malignancies, including breast [24] [25] and col-
orectal [26, 27] cancers.  Among patients with gastric can-
cer, Ghaffazadehgan et al. reported that the CD44 expression 
is correlated with a poor prognosis, especially in those with 
intestinal type of gastric cancer [17].  In an animal model, 
Takaishi et al. reported that only CD44-positive subpopula-
tions of malignant gastric cell lines give rise to xenograft 
tumors in SCID mice and demonstrated that CD44 positivity 
suggests the stem cell properties of self-renewal and differ-
entiation [28].
　CD133 is another putative CSCs marker.  This molecule is 
a pentaspan transmembrane glycoprotein that has been iden-
tified to be a CSC marker in pancreatic [29], ovarian [30], 
and liver cancers [31].  In addition, many reports have shown 
Figure 3. The recurrent-free survival curves for the CSC marker-
positive and -negative gastric cancer patients. The CSC marker-
positive patients exhibited significantly shorter survival times than 
the CSC marker-negative patients according to the log-rank test 
(p=0.019).
Figure 2. The overall survival curves for CSC marker-positive 
and -negative gastric cancer patients. The CSC marker-positive 
patients exhibited significantly shorter survival times than the CSC 
marker-negative patients according to the log-rank test (p=0.006).  
Table 3. Univariate and multivariate analysis of CSCs marker expression and overall survival
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Histology 0.91
   Differentiated referrence
   Undifferentiated 0.96 (0.47-1.95)
Lymphatic invasion 0.09 0.85
   ly0-1 referrence referrence
   ly2-3 1.95 (0.88-4.32) 0.92 (0.38-2.24)
Vessel invasion 0.42
   v0-1 referrence
   v2-3 1.35 (0.65-2.77)
Lymph node metastasis 0.001> 0.001>
   N0-1 referrence referrence
   N2-3 4.34 (2.12-8.88) 3.90 (1.75-8.67)
CSCs marker 0.01> 0.04
   negative referrence referrence
   positive 2.73 (1.29-5.73) 2.22 (1.04-4.76)
Adjuvant chemotherapy 0.60
   no referrence
   yes 1.20 (0.61-2.37)
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that the presence of CD133-positive cells is a significant 
prognostic factor in patients with glioma [32] and colon can-
cer [33, 34].  In gastric cancer patients, previous reports have 
demonstrated that CD133 is positively correlated with tumor 
size, the depth of tumor invasion and the presence of lymph 
node metastasis [19, 20].  Furthermore, multivariate analy-
ses have revealed that CD133 is an independent prognostic 
factor [18, 19].  In an animal study, OʼBrien et al. reported 
that CD133-positive cells share the characteristics of CSCs, 
in which CD133-positive cells are able to initiate tumor 
growth in a minor quantity of cells when transplanted into 
mice [11]. 
　Our results revealed a correlation between combined de-
tection of CSC positivity and clinicopathological features, 
such as lymphatic and vessel invasion. Moreover, the CSC 
marker expression was, second to lymph node metastasis, 
found to be a statistically significant prognostic factor in pa-
tients with T3/4a gastric cancer.  Immunohistochemical 
studies using resected specimens provide morphological in-
formation, such as the amount and distribution of CSC 
marker-positive cells. Theoretically, CSCs should comprise 
a small population of cancer cells in specimens; however, 
our results demonstrated that relatively large areas of the 
specimens exhibited CSC marker positivity and an equal 
distribution of positive cells between the tumor surface and 
more deeply invasive areas.  
　Moreover, contrary to our expectations, we found a quite 
different distribution of CD44 and CD133 positive cells 
even in the same section of the tumor. This implied the pos-
sibility that several CSC clones coexist and compete within 
single primary tumors, as recently indicated in hematopoi-
etic malignancies [35, 36].  An alternative possibility is that 
CD44 and/or CD133 may not represent the CSC population 
itself, but rather a downstream population such as progenitor 
cells.  Wang T et al. also investigated these CSCs marker 
expression in gastric carcinogenesis, as characterized by the 
Correa pathway [37].  The expression of CD44 was found to 
encompass intestinal metaplasia to cancer tissue, whereas 
CD133 was expressed considerably in the latter.  Similar re-
sults were obtained by Wakamatsu et al., who investigated 
the expressions of ALDH, CD44 and CD133 in non-neo-
plastic gastric mucosa and cancer tissue [38].  
　Our present results demonstrate several important points 
for clinical practice.  First, this method is easy to adapt in 
hospitals that are not specialized because only one or two 
specimens of the primary part of the tumor are used for the 
immunohistochemical analysis. Second, the combined de-
tection of CSC markers is useful for selecting T3/4a gastric 
cancer patients with worse prognoses, and our results showed 
that evaluating only two CSC markers is sufficient for such 
selection. 
　In conclusion, the expressions of CSC markers can be 
used to detect gastric cancer patients with poorer prognoses, 
even those in the advanced stage. 
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